JP2008037863A - Pharmaceutical preparation particles containing drug having unpleasant taste - Google Patents
Pharmaceutical preparation particles containing drug having unpleasant taste Download PDFInfo
- Publication number
- JP2008037863A JP2008037863A JP2007179465A JP2007179465A JP2008037863A JP 2008037863 A JP2008037863 A JP 2008037863A JP 2007179465 A JP2007179465 A JP 2007179465A JP 2007179465 A JP2007179465 A JP 2007179465A JP 2008037863 A JP2008037863 A JP 2008037863A
- Authority
- JP
- Japan
- Prior art keywords
- water
- unpleasant taste
- drug
- soluble polymer
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 229940079593 drug Drugs 0.000 title claims abstract description 61
- 235000019640 taste Nutrition 0.000 title claims abstract description 51
- 239000002245 particle Substances 0.000 title claims abstract description 32
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 239000007771 core particle Substances 0.000 claims abstract description 28
- 238000010828 elution Methods 0.000 claims abstract description 24
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 22
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 15
- 229920003176 water-insoluble polymer Polymers 0.000 claims abstract description 11
- 239000011248 coating agent Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 25
- 238000004090 dissolution Methods 0.000 claims description 19
- 238000000576 coating method Methods 0.000 claims description 16
- 230000001747 exhibiting effect Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
- -1 aminoalkyl methacrylate Chemical compound 0.000 claims description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 9
- 229950008138 carmellose Drugs 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229960005069 calcium Drugs 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000004373 Pullulan Substances 0.000 claims description 2
- 229920001218 Pullulan Polymers 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000019423 pullulan Nutrition 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- 239000010410 layer Substances 0.000 description 24
- 230000000873 masking effect Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000008187 granular material Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000005469 granulation Methods 0.000 description 11
- 230000003179 granulation Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- 239000008213 purified water Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000005096 rolling process Methods 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- 229960002544 cloperastine Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229960004708 noscapine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- LVFFZQQWIZURIO-UHFFFAOYSA-N 2-phenylbutanedioic acid Chemical compound OC(=O)CC(C(O)=O)C1=CC=CC=C1 LVFFZQQWIZURIO-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 241000486634 Bena Species 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 1
- AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- MYGVPKMVGSXPCQ-JEDNCBNOSA-N Methylmethionine sulfonium salt Chemical compound [Cl-].C[S+](C)CC[C@H](N)C(O)=O MYGVPKMVGSXPCQ-JEDNCBNOSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- SSOXZAQUVINQSA-BTJKTKAUSA-N Pheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 SSOXZAQUVINQSA-BTJKTKAUSA-N 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- YMEBNAABDXLAJE-GPAWKIAZSA-N [(e)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(e)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-butanoyloxypent-2-en-3-yl]disulfanyl]pent-3-enyl] butanoate Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(/CCOC(=O)CCC)SS\C(CCOC(=O)CCC)=C(/C)N(C=O)CC1=CN=C(C)N=C1N YMEBNAABDXLAJE-GPAWKIAZSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- AMZWNNKNOQSBOP-UHFFFAOYSA-M [n'-(2,5-dioxoimidazolidin-4-yl)carbamimidoyl]oxyaluminum;dihydrate Chemical compound O.O.NC(=O)NC1N=C(O[Al])NC1=O AMZWNNKNOQSBOP-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940043432 albumin tannate Drugs 0.000 description 1
- 229940015825 aldioxa Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 229960000199 bismuth subgallate Drugs 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
- 229950009533 cetraxate Drugs 0.000 description 1
- QSFKGMJOKUZAJM-CNKDKAJDSA-M chembl1578 Chemical compound [Br-].C1[C@H](OC(=O)C(CCC)CCC)C[C@@H]2CC[C@H]1[N+]2(C)C QSFKGMJOKUZAJM-CNKDKAJDSA-M 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229960005058 diphenidol hydrochloride Drugs 0.000 description 1
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 description 1
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- IKALZAKZWHFNIC-JIZZDEOASA-L dipotassium;(2s)-2-aminobutanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O IKALZAKZWHFNIC-JIZZDEOASA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- JQQHKTPQFWSNBC-UHFFFAOYSA-J hydrogen carbonate thorium(4+) Chemical compound [Th+4].OC([O-])=O.OC([O-])=O.OC([O-])=O.OC([O-])=O JQQHKTPQFWSNBC-UHFFFAOYSA-J 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960005469 hydroxocobalamin acetate Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- DQOCFCZRZOAIBN-WZHZPDAFSA-L hydroxycobalamin Chemical compound O.[Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O DQOCFCZRZOAIBN-WZHZPDAFSA-L 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- FGSJNNQVSUVTPW-UHFFFAOYSA-N methoxyphenamine hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1OC FGSJNNQVSUVTPW-UHFFFAOYSA-N 0.000 description 1
- 229960000659 methoxyphenamine hydrochloride Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 229960003207 papaverine hydrochloride Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960001339 pheniramine maleate Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- QFRKWSPTCBGLSU-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzene-1-sulfonate Chemical compound [K+].COC1=CC(S([O-])(=O)=O)=CC=C1O QFRKWSPTCBGLSU-UHFFFAOYSA-M 0.000 description 1
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229950009846 scopolamine butylbromide Drugs 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229960005077 sodium picosulfate Drugs 0.000 description 1
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、不快味を呈する薬物を含有する固形製剤に関する。 The present invention relates to a solid preparation containing a drug exhibiting an unpleasant taste.
イブプロフェン等の刺激性苦味を有する薬物を、散剤や顆粒剤のような粒子径が小さく比表面積が大きい製剤に配合した場合、錠剤の場合と比較して薬物の苦味がより強く感じられる。そこで、これらの製剤の服用性向上の観点から、例えば、特開平９−２０８４５８号公報に、薬物及び組成物中３０重量％以上の水膨潤性物質を含有する組成物を水又は含水アルコールで湿式造粒することにより薬物の不快味をマスキングした経口用製剤が記載されている（特許文献１参照）。 When a drug having an irritating bitter taste such as ibuprofen is blended in a preparation having a small particle size and a large specific surface area such as a powder or granule, the bitter taste of the drug is felt stronger than in the case of a tablet. Therefore, from the viewpoint of improving the dosage of these preparations, for example, in JP-A-9-208458, a composition containing 30% by weight or more of a water-swellable substance in a drug and a composition is wet with water or hydrous alcohol. An oral preparation in which the unpleasant taste of a drug is masked by granulation is described (see Patent Document 1).
また、特表２００３−５０４３２４号公報には、不快な味を有する活性成分と顆粒崩壊剤を含む顆粒に、被覆剤と膜崩壊剤を含む懸濁液を噴霧して被覆することにより不快味をマスキングした顆粒剤が記載されている（特許文献２参照）。しかしながら、この技術では溶出性を改善しようとすると、不快味のマスキングは十分に図れず、一方、十分な不快味のマスキングを図ろうとするとコーティング層を厚くする必要があり、結果として溶出が遅くなるという問題があった。 Also, Japanese Patent Publication No. 2003-504324 discloses an unpleasant taste by spraying a granule containing an active ingredient having an unpleasant taste and a granule disintegrating agent by spraying a suspension containing a coating agent and a membrane disintegrating agent. A masked granule is described (see Patent Document 2). However, this technique cannot sufficiently mask the unpleasant taste if it is intended to improve the dissolution property, but if it is intended to sufficiently mask the unpleasant taste, it is necessary to increase the thickness of the coating layer, resulting in a slow dissolution. There was a problem.
そこで、薬物の溶出性と不快味のマスキングの両方を満足する製剤を得るためには、コーティング剤に配合される成分の選定が重要となっている。例えば、コーティング剤に水不溶性高分子を配合することにより不快味のマスキングを実現し、水溶性高分子を配合することにより溶出性を確保することができる。また、フィルムコーティングにおいては、皮膜量を少なくし、コーティング効率を高める目的で、核粒子に直接被覆される一次皮膜（アンダーコート層）と、アンダーコート層の上に被覆される皮膜（オーバーコート層）の２層のコーティングが施されることがある。 Therefore, in order to obtain a preparation satisfying both drug dissolution and masking of unpleasant taste, selection of components to be blended in the coating agent is important. For example, unpleasant taste masking can be realized by adding a water-insoluble polymer to the coating agent, and elution can be ensured by adding a water-soluble polymer. In film coating, the primary coating (undercoat layer) directly coated on the core particles and the coating (overcoat layer) coated on the undercoat layer for the purpose of reducing the coating amount and increasing the coating efficiency. ) May be applied in two layers.
しかしながら、オーバーコート層のコーティング剤中の水不溶性高分子の配合量が増加すると不快味のマスキング効果は増強するが薬物の溶出が遅くなり、一方、水溶性高分子の配合量が増加すると薬物の溶出は速くなるが不快味のマスキングが不十分となるという問題があった。 However, increasing the amount of water-insoluble polymer in the coating agent of the overcoat layer enhances the masking effect of unpleasant taste but slows the elution of the drug, while increasing the amount of water-soluble polymer increases the drug content. There was a problem that elution was faster but masking of unpleasant taste was insufficient.
よって、本発明の目的は、イブプロフェン等の不快味を呈する薬物を含有し、薬物の不快味が十分にマスキングされ、且つ溶出性が改善された製剤粒子を提供することである。 Accordingly, an object of the present invention is to provide a preparation particle containing a drug exhibiting an unpleasant taste such as ibuprofen, sufficiently masking the unpleasant taste of the drug and having improved dissolution property.
上記課題を解決するために、本発明者らは、鋭意検討を重ねた結果、苦味薬物を含有する核粒子を調製し、水溶性高分子及び少量で薬物の溶出を促進する物質（以下、溶出促進剤とする）を配合したコーティング剤を用いてアンダーコートを施し、さらに、水溶性高分子、水不溶性高分子、及び、溶出促進剤を配合したコーティング剤を用いてオーバーコートを施すことにより、薬物の不快味のマスキングと溶出性が同時に改善される製剤粒子が得られることを見出した。さらに溶出促進剤の選定を鋭意検討した結果、溶出促進剤として、散剤、顆粒剤、錠剤等に配合した場合にこれらの製剤の崩壊性を高めることによって薬物の溶出性を高める性質を有する物質等を用いることにより、さらに不快味が十分にマスキングされ、且つ溶出が速い製剤粒子が得られることを見出し、本発明を完成した。 In order to solve the above-mentioned problems, the present inventors have conducted intensive studies and prepared core particles containing a bitter drug, and a water-soluble polymer and a substance that promotes drug elution with a small amount (hereinafter, elution). By applying an undercoat using a coating agent blended with an accelerator), and further applying an overcoat using a coating agent blended with a water-soluble polymer, a water-insoluble polymer, and an elution accelerator, It has been found that pharmaceutical particles can be obtained in which masking of the unpleasant taste of the drug and dissolution are improved at the same time. Furthermore, as a result of earnest examination of the selection of dissolution enhancers, substances that have the property of enhancing the dissolution properties of drugs by increasing the disintegration properties of these preparations when incorporated in powders, granules, tablets, etc. as dissolution enhancers It was found that by using this, it is possible to obtain formulation particles that are sufficiently masked of unpleasant taste and that are rapidly eluted, thereby completing the present invention.
すなわち本発明は、（１）不快味を呈する薬物を含有する核粒子、（２）水溶性高分子及び溶出促進剤を含有するアンダーコート層、並びに、（３）水溶性高分子、水不溶性高分子、及び、溶出促進剤を含有するオーバーコート層を有する製剤粒子である。 That is, the present invention comprises (1) core particles containing a drug exhibiting an unpleasant taste, (2) an undercoat layer containing a water-soluble polymer and an elution accelerator, and (3) a water-soluble polymer, Formulation particles having an overcoat layer containing molecules and an elution promoter.
本発明によれば、不快味を呈する薬物を含有し、薬物の不快味がマスキングされ、且つ溶出性が改善された製剤粒子を提供することが可能となった。 ADVANTAGE OF THE INVENTION According to this invention, it became possible to provide the formulation particle | grains which contain the drug which exhibits an unpleasant taste, the unpleasant taste of the drug was masked, and the elution property was improved.
本発明の「製剤粒子」は、（１）不快味を呈する薬物を含有する核粒子、（２）水溶性高分子及び溶出促進剤を含有したコーティング剤を用いて前記核粒子をコーティングするアンダーコート層、並びに、（３）水溶性高分子、水不溶性高分子及び溶出促進剤を含有したコーティング剤を用いて前記アンダーコート層の上にコーティングするオーバーコート層を有するものである。 The “formulation particles” of the present invention include (1) core particles containing a drug exhibiting an unpleasant taste, and (2) an undercoat that coats the core particles using a coating agent containing a water-soluble polymer and an elution accelerator. And (3) an overcoat layer coated on the undercoat layer using a coating agent containing a water-soluble polymer, a water-insoluble polymer and an elution accelerator.
「不快味を呈する薬物」とは、苦味や収斂味等を有し、１日当たりの配合量が多い薬物の他、微量であっても数種を配合することにより、不快な呈味を有する薬物の配合量が全体的に多くなる場合も含まれる。１日当たりの配合量が多いものとしては、例えば、イブプロフェン、エテンザミド及びアセトアミノフェンが挙げられる。それ自体の配合量は多くはないが不快な呈味を有する薬物としては、例えば、ウイキョウ油、カンゾウエキス、キキョウ流エキス、ケイヒ油、チョウジ油、ベラドンナエキス、ロートエキスなどの生薬抽出物、ｄ−マレイン酸クロルフェニラミン、Ｌ−アスパラギン酸、Ｌ−アスパラギン酸カリウム、Ｌ−アスパラギン酸マグネシウム、Ｌ−イソロイシン、Ｌ−グルタミン、Ｌ−フェニルアラニン、Ｌ−メチオニン、Ｌ−塩酸ヒスチジン、アスコルビン酸、アスピリン、アズレンスルホン酸ナトリウム、アミノエチルスルホン酸、アルジオキサ、イソプロピルアンチピリン、ウルソデオキシコール酸、エルゴカルシフェロール、オクトチアミン、カフェイン、グアイフェネシン、グアヤコールスルホン酸カリウム、グリチルリチン酸二カリウム、ケイ酸アルミン酸マグネシウム、コハク酸トコフェロール、コレカルシフェロール、コンドロイチン硫酸ナトリウム、サリチルアミド、シアノコバラミン、ジブロフィリン、スクラルファート、セミアルカリプロティナーゼ、タンニン酸アルブミン、タンニン酸ベルベリン、チアミンジスルフィド、テオフィリン、デヒドロコール酸、トラネキサム酸、ニコチン酸アミド、ノスカピン、パルミチン酸レチノール、パントテン酸カルシウム、ビオチン、ピコスルファートナトリウム、ビサコジル、ビスイブチアミン、ビスベンチアミン、ヒベンズ酸チペピジン、フェノールフタリン酸デキストロメトルファン、フェンジゾ酸クロペラスチン、フマル酸クレマスチン、フマル酸第一鉄、フルスルチアミン、ブロムワレリル尿素、ヘスペリジン、ヘプロニカート、ベンフォチアミン、マレイン酸カルビノキサミン、マレイン酸クロルフェニラミン、マレイン酸フェニラミン、メキタジン、メタケイ酸アルミン酸マグネシウム、メチルメチオニンスルホニウムクロリド（ＶＵ）、ヨウ化イソプロパミド、リボフラビン、リン酸コデイン、リン酸ジヒドロコデイン、リン酸ジメモルファン、リン酸ピリドキサール、リン酸リボフラビンナトリウム、リン酸水素カルシウム、安息香酸ナトリウムカフェイン、塩化カルニチン、塩化ベルベリン、塩酸アルギニン、塩酸イソチペンジル、塩酸クロペラスチン、塩酸クロルヘキシジン、塩酸ジサイクロミン、塩酸ジセチアミン、塩酸ジフェニドール、塩酸ジフェニルピラリン、塩酸ジフェンヒドラミン、塩酸セトラキサート、塩酸チアミン、塩酸トリプロリジン、塩酸トリメトキノール、塩酸ノスカピン、塩酸パパベリン、塩酸ヒドロキソコバラミン、塩酸ピリドキシン、塩酸フェニルプロパノールアミン、塩酸フェニレフリン、塩酸フルスルチアミン、塩酸ブロムヘキシン、塩酸メクリジン、塩酸メトキシフェナミン、塩酸ラニチジン、塩酸リジン、塩酸ロペラミド、乾燥水酸化アルミニウムゲル、合成ケイ酸アルミニウム、合成ヒドロタルサイト、酸化マグネシウム、次没食子酸ビスマス、酒石酸アリメマジン、臭化ブチルスコポラミン、臭化メチルアトロピン、臭化メチルオクタトロピン、臭化メチルベナクチジウム、臭化水素酸スコポラミン、臭化水素酸デキストロメトルファン、硝酸チアミン、酢酸トコフェロール、酢酸ヒドロキソコバラミン、水酸化アルミニウム・炭酸水素ナトリウム共沈物、水酸化マグネシウム、炭酸マグネシウム、炭酸水素ナトリウム、沈降炭酸カルシウム、銅クロロフィリンナトリウム、乳酸カルシウム、無水カフェイン、葉酸、酪酸リボフラビンが挙げられる。不快味のマスキングの必要性という観点から、イブプロフェンに代表される製剤中に多量に配合する薬物の場合に本発明の効果がより大きい。また，微量であっても数種を配合することにより、不快味を呈する薬物の配合量が全体的に多くなる場合も含まれる。また、本発明における不快味を呈する薬物の配合量は、例えば不快味を呈する薬物がイブプロフェンである場合、前記不快味を呈する薬物を含有する核粒子の質量に対して30質量％以上，より好ましくは35重量％以上であると本発明を用いる意義がある。 “A drug exhibiting an unpleasant taste” means a drug having an unpleasant taste by blending several kinds of drugs in addition to a drug having a bitter taste, an astringent taste, etc. It is also included when the amount of is increased as a whole. Examples of the compound having a large amount per day include ibuprofen, etenzamide, and acetaminophen. Examples of drugs having an unpleasant taste, although the amount per se is not large, include, for example, herbal extracts such as fennel oil, licorice extract, fennel extract, cinnamon oil, clove oil, belladonna extract, funnel extract, d -Chlorpheniramine maleate, L-aspartic acid, potassium L-aspartate, magnesium L-aspartate, L-isoleucine, L-glutamine, L-phenylalanine, L-methionine, L-histidine hydrochloride, ascorbic acid, aspirin, Sodium azulenesulfonate, aminoethylsulfonic acid, aldioxa, isopropylantipyrine, ursodeoxycholic acid, ergocalciferol, octothiamine, caffeine, guaifenesin, potassium guaiacolsulfonate, dipotassium glycyrrhizinate , Magnesium aluminate, tocopherol succinate, cholecalciferol, sodium chondroitin sulfate, salicylamide, cyanocobalamin, dibrofilin, sucralfate, semi-alkali proteinase, albumin tannate, berberine tannate, thiamine disulfide, theophylline, dehydrocholic acid, tranexam Acid, nicotinamide, noscapine, retinol palmitate, calcium pantothenate, biotin, sodium picosulfate, bisacodyl, bisbutiamine, bisbenchamine, tipepidine hibenzate, dextromethorphan of phenolphthalate, cloperastine fendizoate, fumarate Cremastine acid, ferrous fumarate, fursultiamine, bromvalerylurea, hesperidin Hepronicart, benfotiamine, carbinoxamine maleate, chlorpheniramine maleate, pheniramine maleate, mequitazine, magnesium aluminate metasilicate, methylmethionine sulfonium chloride (VU), isopropamide iodide, riboflavin, codeine phosphate, dihydrocodeine phosphate, Dimemorphan phosphate, pyridoxal phosphate, sodium riboflavin phosphate, calcium hydrogen phosphate, sodium benzoate caffeine, carnitine chloride, berberine chloride, arginine hydrochloride, istipendyl hydrochloride, cloperastine hydrochloride, chlorhexidine hydrochloride, dicyclomine hydrochloride, dicetiamine hydrochloride, diphenidol hydrochloride Diphenylpyraline hydrochloride, diphenhydramine hydrochloride, cetraxate hydrochloride, thiamine hydrochloride, Riprolysine, Trimethoquinol hydrochloride, Noscapine hydrochloride, Papaverine hydrochloride, Hydroxocobalamin hydrochloride, Pyridoxine hydrochloride, Phenylpropanolamine hydrochloride, Phenylephrine hydrochloride, Flurthiamine hydrochloride, Bromhexine hydrochloride, Meclizine hydrochloride, Methoxyphenamine hydrochloride, Lanitidine hydrochloride, Lysine hydrochloride, Loperamide hydrochloride, dry aluminum hydroxide gel, synthetic aluminum silicate, synthetic hydrotalcite, magnesium oxide, bismuth subgallate, alimemazine tartrate, butyl scopolamine bromide, methyl atropine bromide, methyl octatropine bromide, methyl bena bromide Cutidium, scopolamine hydrobromide, dextromethorphan hydrobromide, thiamine nitrate, tocopherol acetate, hydroxocobalamin acetate, aluminum hydroxide and hydrogen carbonate Thorium coprecipitate, magnesium hydroxide, magnesium carbonate, sodium hydrogen carbonate, precipitated calcium carbonate, sodium copper chlorophyllin, calcium lactate, anhydrous caffeine, folic acid, and a riboflavin butyrate. From the viewpoint of necessity of masking of unpleasant taste, the effect of the present invention is greater in the case of a drug incorporated in a large amount in a preparation typified by ibuprofen. Moreover, even if it is a trace amount, the case where the compounding quantity of the drug which exhibits an unpleasant taste increases as a whole is also included by mix | blending several types. In addition, the compounding amount of the drug exhibiting an unpleasant taste in the present invention is, for example, 30% by mass or more with respect to the mass of the core particles containing the drug exhibiting the unpleasant taste, when the drug exhibiting the unpleasant taste is ibuprofen. If it is 35% by weight or more, it is meaningful to use the present invention.
前記不快味を呈する薬物を含有する核粒子は、例えば、不快味を呈する薬物を添加成分と混合し、ヒドロキシプロピルセルロース等の水溶性高分子を溶媒（水又は水及びエタノールの混合液）に溶解した溶液を用いて造粒することにより得られる。また、このように造粒する方法としては、例えば、撹拌造粒法、流動層造粒法、転動流動造粒法、練合造粒法、押し出し造粒法、乾式造粒法、噴霧造粒法、積層造粒法，転動造粒法等が挙げられる。さらに、苦味薬物を含有する核粒子の平均粒子径は、100〜500μｍの範囲であることが好ましい ここで、本発明における「平均粒子径（mean particle diameter）」とは、質量平均径である。具体的には、サンプリングした粒子（例えば５ｇ）を、３０Ｍ（５００μｍ）、４２Ｍ（３５５μｍ）、６０Ｍ（２５０μｍ）、８０Ｍ（１８０μｍ）、１００Ｍ（１５０μｍ）、１５０Ｍ（１０６μｍ）、２００Ｍ（７５μｍ）及び２７０Ｍ（５３μｍ）の順に積み重ねた篩上に置き、一定時間（例えば、３分間）振動を与えて分級し、３０Ｍ篩残、４２Ｍ篩残、６０Ｍ篩残、８０Ｍ篩残、１００Ｍ篩残、１５０Ｍ篩残、２００Ｍ篩残、２７０Ｍ篩残及び２７０Ｍ通過分の各質量を測定する。各質量に、予め算出しておいた各篩間の粒径区分の中央値を乗じ、その総和を全質量（５ｇ）で除した値が求める質量平均径、すなわち、本発明における平均粒子径である。例えば、ロッボットシフター（株式会社セイシン企業）などを用いれば自動的に測定できる。なお、Ｍはメッシュを表す。なお、平均粒子径については、社団法人化学工学会編「現代の化学工学Ｉ」（１９８８年、朝倉書店、ｐ．２３９〜ｐ．２４５）に依った。 The core particles containing a drug exhibiting an unpleasant taste are, for example, a drug exhibiting an unpleasant taste mixed with an additive component, and a water-soluble polymer such as hydroxypropylcellulose is dissolved in a solvent (water or a mixture of water and ethanol). It is obtained by granulating using the prepared solution. Examples of the granulation method include stirring granulation method, fluidized bed granulation method, rolling fluid granulation method, kneading granulation method, extrusion granulation method, dry granulation method, spray granulation method, and the like. Examples thereof include a granulation method, a lamination granulation method, and a rolling granulation method. Furthermore, the average particle diameter of the core particles containing the bitter drug is preferably in the range of 100 to 500 μm. Here, the “mean particle diameter” in the present invention is a mass average diameter. Specifically, the sampled particles (for example, 5 g) are 30M (500 μm), 42M (355 μm), 60M (250 μm), 80M (180 μm), 100M (150 μm), 150M (106 μm), 200M (75 μm), and 270M. (53 μm) placed on a sieve stacked in order, classified by applying vibration for a certain time (for example, 3 minutes), 30M sieve residue, 42M sieve residue, 60M sieve residue, 80M sieve residue, 100M sieve residue, 150M sieve residue , 200M sieve residue, 270M sieve residue and 270M passage mass is measured. Multiply each mass by the median value of the particle size classification between each sieve that has been calculated in advance, and obtain the mass average diameter obtained by dividing the sum by the total mass (5 g), that is, the average particle size in the present invention. is there. For example, it can be automatically measured by using a robot shifter (seishin corporation). M represents a mesh. The average particle size depends on “Modern Chemical Engineering I” (1988, Asakura Shoten, p.239-p.245) edited by the Chemical Society of Japan.
さらに、前記不快味を呈する薬物を含有する核粒子には、他の公知の添加剤を配合してもよい。公知の添加剤としては、例えば、軽質無水ケイ酸、含水二酸化ケイ素、結晶セルロース、カルボキシメチルスターチナトリウム、ヒドロキシプロピルスターチ、低置換度ヒドロキシプロピルセルロース、クロスカルメロース、クロスカルメロースナトリウム、アメ粉（Maltose Syrup Powder）、粉糖、エリスルトール、キシリトール、ソルビトール、マルチトール、ラクチトール、白糖、無水マルトース及び含水マルトースを挙げることができる。 Furthermore, you may mix | blend another well-known additive with the core particle containing the medicine which exhibits the said unpleasant taste. Known additives include, for example, light anhydrous silicic acid, hydrous silicon dioxide, crystalline cellulose, sodium carboxymethyl starch, hydroxypropyl starch, low-substituted hydroxypropylcellulose, croscarmellose, croscarmellose sodium, candy powder (Maltose Syrup Powder), powdered sugar, erythritol, xylitol, sorbitol, maltitol, lactitol, sucrose, anhydrous maltose and hydrous maltose.
本発明の「アンダーコート層」とは、核粒子を直接被覆する層であり、「オーバーコート層」とは、アンダーコート層を被覆する層である。 The “undercoat layer” in the present invention is a layer that directly covers the core particles, and the “overcoat layer” is a layer that covers the undercoat layer.
本発明の「溶出促進剤」とは、散剤、顆粒剤、錠剤等に配合した場合にこれらの製剤の崩壊性を高めることにより薬物の溶出性を高める性質を有する物質等であり、崩壊剤や、水に対する溶解度が15質量％以上である糖アルコールが挙げられ、崩壊剤としては、例えばカルメロースカルシウム、クロスカルメロースナトリウム、低置換度ヒドロキシプロピルセルロース、カルメロース、カルメロースナトリウム、デンプン、部分アルファ化デンプン、カルボキシメチルスターチナトリウム、プルランが挙げられ、水に対する溶解度が15%以上である糖アルコールとしては、例えばマンニトール、エリスリトール、キシリトール，ソルビトール、マルチトール，ラクチトールが挙げられる。これらの中でも、製剤中の薬物の安定化の観点から、例えば不快味を呈する薬物がイブプロフェンである場合は、カルメロースカルシウムやマンニトールのような薬物と反応性のない物質が好ましい。溶出促進剤の配合量は、薬物の溶出性の改善と製剤の大きさの観点から、コーティング剤の全体質量に対して、1〜20質量％の範囲であることが好ましい。 The “dissolution enhancer” of the present invention is a substance having a property of enhancing the dissolution property of a drug by enhancing the disintegration property of these preparations when blended in powders, granules, tablets, etc. Sugar alcohol having a solubility in water of 15% by mass or more. Examples of the disintegrant include carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, carmellose, carmellose sodium, starch, and partially pregelatinized. Examples thereof include starch, sodium carboxymethyl starch, and pullulan. Examples of sugar alcohols having a solubility in water of 15% or more include mannitol, erythritol, xylitol, sorbitol, maltitol, and lactitol. Among these, from the viewpoint of stabilizing the drug in the preparation, for example, when the drug exhibiting an unpleasant taste is ibuprofen, a substance that is not reactive with the drug such as carmellose calcium or mannitol is preferable. The blending amount of the elution accelerator is preferably in the range of 1 to 20% by mass with respect to the total mass of the coating agent from the viewpoint of improving the drug elution and the size of the preparation.
本発明のコーティング剤に配合される水溶性高分子としては、通常各種固形製剤のコーティング剤として使用されるものであればよく、例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ポリビニルピロリドン、ポリビニルアルコール、メチルセルロースを挙げることができる。これらの水溶性高分子の中でも、薬物の不快味マスキング及び薬物の溶出性の観点から、ヒドロキシプロピルメチルセルロースが好ましい。さらに、前記水溶性高分子の配合量は、薬物の不快味マスキング及び薬物の溶出性の観点から、コーティング剤全体質量に対して40〜80質量％の範囲であることが好ましい。 The water-soluble polymer blended in the coating agent of the present invention may be any one that is usually used as a coating agent for various solid preparations. For example, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, methylcellulose Can be mentioned. Among these water-soluble polymers, hydroxypropylmethylcellulose is preferred from the viewpoint of unpleasant taste masking of drugs and drug elution. Furthermore, the blending amount of the water-soluble polymer is preferably in the range of 40 to 80% by mass with respect to the total mass of the coating agent from the viewpoint of drug unpleasant taste masking and drug elution.
本発明のコーティング剤に配合される水不溶性高分子としては、通常各種固形製剤のコーティング剤として使用されるものであればよく、例えば、エチルセルロース、アミノアルキルメタアクリレート、ポリビニルアセタールジエチルアミノアセテートを挙げることができる。これらの水不溶性高分子の中でも、薬物の不快味マスキング及び薬物の溶出性の観点から、エチルセルロースが好ましい。さらに、前記水溶性高分子の配合量は、薬物の不快味マスキング及び薬物の溶出性の観点から、コーティング剤全体質量に対して10〜59質量％の範囲であることが好ましい。 The water-insoluble polymer to be blended in the coating agent of the present invention is not limited as long as it is usually used as a coating agent for various solid preparations, and examples thereof include ethyl cellulose, aminoalkyl methacrylate, and polyvinyl acetal diethylaminoacetate. it can. Among these water-insoluble polymers, ethyl cellulose is preferable from the viewpoint of unpleasant taste masking of drugs and drug elution. Furthermore, the blending amount of the water-soluble polymer is preferably in the range of 10 to 59% by mass with respect to the total mass of the coating agent from the viewpoint of drug unpleasant taste masking and drug dissolution.
また、本発明の製剤粒子は、製剤粒子同士の凝集を防止するために、コーティング剤に滑沢剤及び／又は流動化剤を配合する必要がある。滑沢剤及び流動化剤としては、例えば含水二酸化ケイ素、軽質無水ケイ酸、酸化チタン、ステアリン酸マグネシウム、ステアリン酸カルシウム、メタケイ酸アルミン酸マグネシウム、タルクが挙げられる。これらの中でも、イブプロフェンのような他の成分と反応性の高い薬物との配合禁忌の観点からタルクが好ましい。さらに滑沢剤及び／又は流動化剤の配合量は、滑沢化剤としてタルクを用いる場合は、コーティング剤全体質量に対して10〜50質量％、好ましくは15〜45質量％である。10質量％に満たないと、期待される凝集防止、滑沢効果が得られず、また50質量％を超えると、フィルムの成形性に影響を及ぼし十分な苦味マスキング効果が得られない。 In addition, the preparation particles of the present invention need to contain a lubricant and / or a fluidizing agent in the coating agent in order to prevent aggregation of the preparation particles. Examples of the lubricant and the fluidizing agent include hydrous silicon dioxide, light anhydrous silicic acid, titanium oxide, magnesium stearate, calcium stearate, magnesium aluminate metasilicate, and talc. Among these, talc is preferable from the viewpoint of contraindication of other components such as ibuprofen and a highly reactive drug. Furthermore, the blending amount of the lubricant and / or the fluidizing agent is 10 to 50% by mass, preferably 15 to 45% by mass, based on the total mass of the coating agent when talc is used as the lubricant. If it is less than 10% by mass, the expected aggregation prevention and lubrication effects cannot be obtained, and if it exceeds 50% by mass, the moldability of the film is affected and a sufficient bitterness masking effect cannot be obtained.
本発明のコーティング層は、前記溶出促進剤及び水溶性高分子を含有し且つ前記核粒子を覆うアンダーコート層と、前記溶出促進剤、水溶性高分子、及び、水不溶性高分子を含有し前記アンダーコート層を覆うオーバーコート層の２層からなる層である。このようなコーティング層の製剤粒子の質量に対する割合としては、不快味のマスキング、薬物の溶出性、薬物の安定性等の観点から、6〜30質量％の範囲が好ましい。 The coating layer of the present invention contains the elution accelerator and the water-soluble polymer and covers the core particle, the elution accelerator, the water-soluble polymer, and the water-insoluble polymer. It is a layer composed of two layers of an overcoat layer covering the undercoat layer. The ratio of the coating layer to the mass of the preparation particles is preferably in the range of 6 to 30% by mass from the viewpoint of unpleasant taste masking, drug dissolution, drug stability, and the like.
本発明の製剤粒子は、核粒子にアンダーコート層を被覆することにより、その上のオーバーコート層を薄く均一に被覆することができることから、従来のフィルムコーティングと比較して被覆量を少なくすることができる。これにより、従来のコーティング製剤と比較して粒子径を大きくすることなく、不快味のマスキングを確保することができる。核粒子に対するアンダーコート層及びオーバーコート層の割合は、核粒子の質量に対して、アンダーコート層が1〜10質量％、オーバーコート層が5〜20質量％である。 In the preparation particles of the present invention, by coating the undercoat layer on the core particles, the overcoat layer thereon can be thinly and uniformly coated, so that the coating amount can be reduced compared with the conventional film coating. Can do. Thereby, masking of an unpleasant taste can be ensured, without enlarging a particle diameter compared with the conventional coating formulation. The ratio of the undercoat layer and the overcoat layer to the core particles is 1 to 10% by mass for the undercoat layer and 5 to 20% by mass for the overcoat layer with respect to the mass of the core particles.
また、前記核粒子を前記コーティング層でコーティングする方法としては、一般的な方法を用いることができ、例えば、流動層コーティング法、転動流動層コーティング法、転動流動コーティング法、パンコーティング法等が挙げられる。 In addition, as a method of coating the core particles with the coating layer, a general method can be used, for example, a fluidized bed coating method, a rolling fluidized bed coating method, a rolling fluidized coating method, a pan coating method, or the like. Is mentioned.
本発明の製剤粒子は、さらに賦形剤あるいは他の成分と混合した後に、常法により各種固形製剤に調製することができる。各種固形製剤としては、例えば、顆粒剤、散剤、丸剤、錠剤、カプセル剤を挙げることができる。 The preparation particles of the present invention can be prepared into various solid preparations by a conventional method after further mixing with an excipient or other components. Examples of various solid preparations include granules, powders, pills, tablets, and capsules.
以下に参考例、実施例、比較例及び試験例を挙げ、本発明をより詳しく説明する。実施例は本発明の実施の形態を具体的に示す例であり、試験例は実施例を評価した試験の例である。本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference examples, examples, comparative examples and test examples. An example is an example which shows an embodiment of the invention concretely, and a test example is an example of a test which evaluated an example. The present invention is not limited to these examples.
参考例１
核粒子の製造法
イブプロフェン27000g、リボフラビン240g、軽質無水ケイ酸3000g、結晶セルロース12000g、アメ粉21000gを秤量、混合し、粉砕したものを、ヒドロキシプロピルセルロース（ＨＰＣ−Ｌ）5400gを精製水54600gに溶解した溶液を結合液として、転動流動層造粒機（ＭＰ：パウレック社製）を用いて造粒し、核粒子を製造した。核粒子の平均粒子径は306μｍ、かさ密度は421.7kg/m3であった。(かさ密度の測定方法：体積既知の容器（例えば、直径３０ｍｍ、１００ｍＬの円柱状容器）に粉体試料を加え、粉体の表面を擦り切って秤量し、このときの粉体試料の質量を容器の内容量で除した値である。この際、容器のタッピングは行わない。見掛け比重ともいう。本発明において「かさ密度」の測定には、筒井理化学社製のＡ．Ｂ．Ｄ粉体測定器を用いた。)
Reference example 1
Production method of core particles 27000g of ibuprofen, 240g of riboflavin, 3000g of light anhydrous silicic acid, 12000g of crystalline cellulose, 21000g of candy powder, weighed, mixed and pulverized, dissolved 5400g of hydroxypropylcellulose (HPC-L) in 54600g of purified water The obtained solution was used as a binding liquid, and granulated using a rolling fluidized bed granulator (MP: manufactured by POWREC) to produce core particles. The average particle diameter of the core particles was 306 μm, and the bulk density was 421.7 kg / m 3 . (Measurement method of bulk density: Add a powder sample to a container with a known volume (for example, a cylindrical container with a diameter of 30 mm, 100 mL), scrape the surface of the powder, weigh, and measure the mass of the powder sample at this time. The value divided by the inner volume of the container, in which case the container is not tapped, which is also referred to as apparent specific gravity. (A measuring instrument was used.)
参考例２
核粒子の製造法
イブプロフェン27000g、リボフラビン240g、軽質無水ケイ酸3000g、結晶セルロース12000g、アメ粉21000gを秤量、混合し、粉砕したものを、ヒドロキシプロピルセルロース（ＨＰＣ−Ｌ）5400gを精製水48600gに溶解した溶液を結合液として、転動流動層造粒機（ＭＰ：パウレック社製）を用いて造粒し、核粒子を製造した。核粒子の平均粒子径は281μｍ、かさ密度は429.0kg/m3であった。
Reference example 2
Production method of core particles 27000g of ibuprofen, 240g of riboflavin, 3000g of light anhydrous silicic acid, 12000g of crystalline cellulose, 21000g of candy powder, weighed, mixed and pulverized, dissolved 5400g of hydroxypropyl cellulose (HPC-L) in 48600g of purified water The obtained solution was used as a binding liquid, and granulated using a rolling fluidized bed granulator (MP: manufactured by POWREC) to produce core particles. The average particle diameter of the core particles was 281 μm, and the bulk density was 429.0 kg / m 3 .
実施例１
参考例１で得られた核粒子を、ヒドロキシプロピルメチルセルロース34.2g、タルク22.8g及びカルメロースカルシウム5.7gを精製水575gに溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施し、乾燥した後に、エチルセルロース46.2g、ヒドロキシプロピルメチルセルロース27.6g及びタルク49.2g及びカルメロースカルシウム12.3gを、エタノール1131g及び精製水283gの混合液に溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施して、顆粒を製造した。
Example 1
The core particle obtained in Reference Example 1 is a coating agent obtained by dissolving and dispersing 34.2 g of hydroxypropylmethylcellulose, 22.8 g of talc and 5.7 g of carmellose calcium in 575 g of purified water, and a spouted bed with a draft tube (GPCG: After coating and drying, 46.2 g of ethylcellulose, 27.6 g of hydroxypropylmethylcellulose and 49.2 g of talc and 12.3 g of carmellose calcium were dissolved and dispersed in a mixture of 1131 g of ethanol and 283 g of purified water. The obtained coating agent was coated using a spouted bed with a draft tube (GPCG: manufactured by Paulek) to produce granules.
実施例２
参考例２で得られた核粒子を、ヒドロキシプロピルメチルセルロース34.2g、タルク22.8g及びマンニトール5.7gを精製水575gに溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施し、乾燥した後に、エチルセルロース46.2g、ヒドロキシプロピルメチルセルロース27.6g、タルク49.2g及びカルメロースカルシウム12.3gを、エタノール1131g及び精製水283gの混合液に溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施して、顆粒を製造した。
Example 2
The core particle obtained in Reference Example 2 is a coating agent obtained by dissolving and dispersing 34.2 g of hydroxypropylmethylcellulose, 22.8 g of talc and 5.7 g of mannitol in 575 g of purified water, and a spouted bed with a draft tube (GPCG: Paulec) Can be dissolved and dispersed in a mixed solution of 1131 g of ethanol and 283 g of purified water. 46.2 g of ethylcellulose, 27.6 g of hydroxypropylmethylcellulose, 49.2 g of talc and 12.3 g of carmellose calcium The resulting coating agent was coated using a spouted bed with a draft tube (GPCG: manufactured by Paulek) to produce granules.
比較例１
参考例１で得られた核粒子を、ヒドロキシプロピルメチルセルロース34.2g及びタルク22.8gを精製水575gに溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施し、乾燥した後に、エチルセルロース46.2g、ヒドロキシプロピルメチルセルロース27.6g及びタルク49.2gを、エタノール1131g及び精製水283gの混合液に溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施して、顆粒を製造した。
Comparative Example 1
A coating agent obtained by dissolving and dispersing 34.2 g of hydroxypropylmethylcellulose and 22.8 g of talc in 575 g of purified water from the core particles obtained in Reference Example 1, and using a spouted bed with a draft tube (GPCG: manufactured by Paulec) After coating and drying, a spouted bed with a draft tube is a coating agent obtained by dissolving and dispersing 46.2 g of ethylcellulose, 27.6 g of hydroxypropylmethylcellulose and 49.2 g of talc in a mixed solution of 1131 g of ethanol and 283 g of purified water. Granules were produced by coating using GPCG (manufactured by Paulek).
比較例２
参考例２で得られた核粒子を、エチルセルロース46.2g、ヒドロキシプロピルメチルセルロース27.6g、タルク49.2g及びカルメロースカルシウム12.3gを、エタノール1131g及び精製水283gの混合液に溶解・分散し得られたコーティング剤で、ドラフトチューブ付き噴流層（ＧＰＣＧ：パウレック社製）を用いてコーティングを施して、顆粒を製造した。
Comparative Example 2
Coating obtained by dissolving and dispersing 46.2 g of ethyl cellulose, 27.6 g of hydroxypropylmethylcellulose, 49.2 g of talc and 12.3 g of carmellose calcium in a mixed solution of 1131 g of ethanol and 283 g of purified water. Using an agent, a spouted bed with a draft tube (GPCG: manufactured by Paulek) was applied to produce granules.
試験例
実施例１及び２並びに比較例１及び２で調製したコーティング顆粒と、薬物及び賦形剤を秤量、混合、粉砕し、アルコール95%溶液を溶媒として高速撹拌造粒（バーチカルグラニュレーター：パウレック社製）を行うことにより得られた薬物を含有する顆粒を混合した処方を、試験サンプルとした。試験サンプルを、日本薬局方一般試験法溶出試験法パドル法にて試験液に水を用いて溶出試験を実施した。試験結果を図１に示した。
Test Example The coated granules prepared in Examples 1 and 2 and Comparative Examples 1 and 2, and drugs and excipients are weighed, mixed and pulverized, and granulated at high speed using a 95% alcohol solution as a solvent (vertical granulator: POWREC A test sample was prepared by mixing granules containing a drug obtained by performing a test. The test sample was subjected to a dissolution test using water as a test solution by the Japanese Pharmacopoeia General Test Method Dissolution Test Method Paddle Method. The test results are shown in FIG.
試験サンプルを透明ビンに充填、密栓し、5℃および65℃で１週間保存した後、サンプル中のイブプロフェンをＨＰＬＣ法により定量を行い、残存率を評価した。試験結果を表１に示した。 The test sample was filled in a transparent bottle, sealed, and stored at 5 ° C. and 65 ° C. for 1 week, and then ibuprofen in the sample was quantified by HPLC method to evaluate the residual rate. The test results are shown in Table 1.
試験サンプルの風味評価を試験者３名で行い、１名以上が苦味を感じたサンプルを△とした。結果を表２に示した。 The flavor evaluation of the test sample was performed by three testers, and a sample in which one or more felt bitterness was indicated by Δ. The results are shown in Table 2.
比較例１では、不快味のマスキングは十分であったが、溶出が遅延する傾向が確認できた。比較例２では、溶出は速やかであったが、不快味のマスキングが不十分であった。一方、実施例１及び２では、溶出性が良好であり且つ不快味のマスキングも十分であった。また、実施例及び比較例において、薬物の安定性は同等であった。
以上の結果より、イブプロフェン等の不快味を呈する薬物を含有し、薬物の不快味が十分にマスキングされ、且つ溶出性が改善された製剤粒子を提供することができた。
In Comparative Example 1, masking of unpleasant taste was sufficient, but a tendency of elution to be delayed was confirmed. In Comparative Example 2, dissolution was rapid, but masking of unpleasant taste was insufficient. On the other hand, in Examples 1 and 2, the dissolution property was good and the masking of unpleasant taste was sufficient. Moreover, the stability of the drug was comparable in the examples and comparative examples.
From the above results, it was possible to provide a preparation particle containing a drug exhibiting an unpleasant taste such as ibuprofen, sufficiently masking the unpleasant taste of the drug, and having improved dissolution property.
本発明によって、イブプロフェンのような不快味を呈する薬物を高濃度に含有しつつ、不快味のマスキング性に優れ、溶出の速い顆粒剤、散剤等を提供することが期待できる。 According to the present invention, it can be expected to provide granules, powders and the like that are excellent in unpleasant taste masking properties and rapidly dissolve while containing a drug having an unpleasant taste such as ibuprofen at a high concentration.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007179465A JP5141115B2 (en) | 2006-07-11 | 2007-07-09 | Drug-containing preparation particles exhibiting an unpleasant taste |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006190144 | 2006-07-11 | ||
| JP2006190144 | 2006-07-11 | ||
| JP2007179465A JP5141115B2 (en) | 2006-07-11 | 2007-07-09 | Drug-containing preparation particles exhibiting an unpleasant taste |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008037863A true JP2008037863A (en) | 2008-02-21 |
| JP5141115B2 JP5141115B2 (en) | 2013-02-13 |
Family
ID=39173292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007179465A Expired - Fee Related JP5141115B2 (en) | 2006-07-11 | 2007-07-09 | Drug-containing preparation particles exhibiting an unpleasant taste |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5141115B2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010037326A (en) * | 2008-07-10 | 2010-02-18 | Taisho Pharmaceutical Co Ltd | Drug particle for carrying medicine having unpleasant taste |
| WO2010018614A1 (en) * | 2008-08-11 | 2010-02-18 | 味の素株式会社 | Hydrophilic amino acid-containing preparation having improved taste |
| JP2011125331A (en) * | 2009-11-17 | 2011-06-30 | Taisho Pharmaceutical Co Ltd | Scale powder-containing coating tablet |
| JP2011136922A (en) * | 2009-12-28 | 2011-07-14 | Lion Corp | Ibuprofen-containing pharmaceutical preparation |
| JP2012046493A (en) * | 2010-07-30 | 2012-03-08 | Taisho Pharmaceutical Co Ltd | Oral liquid medicine |
| JP2012240917A (en) * | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | Fine particle for preparation and medication containing the same |
| JP2015221781A (en) * | 2014-04-30 | 2015-12-10 | 大正製薬株式会社 | Solid preparations |
| JP2016060731A (en) * | 2014-09-19 | 2016-04-25 | エスエス製薬株式会社 | Oral composition |
| WO2017146052A1 (en) * | 2016-02-23 | 2017-08-31 | ニプロ株式会社 | Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles |
| KR20200001993A (en) | 2018-06-28 | 2020-01-07 | 라이온 가부시키가이샤 | Composition for internal use and method of product thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201724A (en) * | 1982-05-17 | 1983-11-24 | Shin Etsu Chem Co Ltd | Coating composition for solid pharmaceutical preparation |
| JP2000281564A (en) * | 1998-05-18 | 2000-10-10 | Takeda Chem Ind Ltd | Medicinal preparation |
| JP2001172201A (en) * | 1999-12-20 | 2001-06-26 | Basf Ag | Use of film coating for masking the taste for oral administration, oral administration form and production thereof |
| WO2005117845A1 (en) * | 2004-06-03 | 2005-12-15 | Taisho Pharmaceutical Co., Ltd. | Oral preparations and process for production thereof |
| US20060115539A1 (en) * | 2003-06-07 | 2006-06-01 | Armin Prasch | Micropellets method for the production thereof, and use thereof |
-
2007
- 2007-07-09 JP JP2007179465A patent/JP5141115B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58201724A (en) * | 1982-05-17 | 1983-11-24 | Shin Etsu Chem Co Ltd | Coating composition for solid pharmaceutical preparation |
| JP2000281564A (en) * | 1998-05-18 | 2000-10-10 | Takeda Chem Ind Ltd | Medicinal preparation |
| JP2001172201A (en) * | 1999-12-20 | 2001-06-26 | Basf Ag | Use of film coating for masking the taste for oral administration, oral administration form and production thereof |
| US20060115539A1 (en) * | 2003-06-07 | 2006-06-01 | Armin Prasch | Micropellets method for the production thereof, and use thereof |
| WO2005117845A1 (en) * | 2004-06-03 | 2005-12-15 | Taisho Pharmaceutical Co., Ltd. | Oral preparations and process for production thereof |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010037326A (en) * | 2008-07-10 | 2010-02-18 | Taisho Pharmaceutical Co Ltd | Drug particle for carrying medicine having unpleasant taste |
| WO2010018614A1 (en) * | 2008-08-11 | 2010-02-18 | 味の素株式会社 | Hydrophilic amino acid-containing preparation having improved taste |
| JP2011125331A (en) * | 2009-11-17 | 2011-06-30 | Taisho Pharmaceutical Co Ltd | Scale powder-containing coating tablet |
| JP2011136922A (en) * | 2009-12-28 | 2011-07-14 | Lion Corp | Ibuprofen-containing pharmaceutical preparation |
| JP2012046493A (en) * | 2010-07-30 | 2012-03-08 | Taisho Pharmaceutical Co Ltd | Oral liquid medicine |
| JP2012240917A (en) * | 2011-05-16 | 2012-12-10 | Zensei Yakuhin Kogyo Kk | Fine particle for preparation and medication containing the same |
| JP2015221781A (en) * | 2014-04-30 | 2015-12-10 | 大正製薬株式会社 | Solid preparations |
| JP2019131614A (en) * | 2014-04-30 | 2019-08-08 | 大正製薬株式会社 | Solid preparation |
| JP2019131615A (en) * | 2014-04-30 | 2019-08-08 | 大正製薬株式会社 | Solid preparation |
| JP2016060731A (en) * | 2014-09-19 | 2016-04-25 | エスエス製薬株式会社 | Oral composition |
| WO2017146052A1 (en) * | 2016-02-23 | 2017-08-31 | ニプロ株式会社 | Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles |
| JPWO2017146052A1 (en) * | 2016-02-23 | 2018-12-13 | ニプロ株式会社 | Pharmaceutical composition particles, orally disintegrating preparations containing the same, and method for producing pharmaceutical composition particles |
| US20190054029A1 (en) * | 2016-02-23 | 2019-02-21 | Nipro Corporation | Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles |
| KR20200001993A (en) | 2018-06-28 | 2020-01-07 | 라이온 가부시키가이샤 | Composition for internal use and method of product thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5141115B2 (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5141115B2 (en) | Drug-containing preparation particles exhibiting an unpleasant taste | |
| JP5777273B2 (en) | Formulation particles containing drug with unpleasant taste | |
| JP6062168B2 (en) | Formulation containing herbal medicine-derived component and method for producing the same | |
| JP5974469B2 (en) | Tablet manufacturing method | |
| JP4853818B2 (en) | Solid formulation containing ibuprofen and ambroxol hydrochloride | |
| JP2000178182A (en) | Disintegrable composition | |
| JP5664225B2 (en) | Unpleasant taste masking particles and oral preparations containing the same | |
| JP2017075139A (en) | Orally disintegrating tablet containing low-dose drug | |
| JPWO2017047586A1 (en) | tablet | |
| JP2001316249A (en) | Tablet-type medicinal composition | |
| JP5828280B2 (en) | Tablet and production method thereof | |
| JP4716063B2 (en) | Unpleasant taste masking particles and oral preparations containing the same | |
| JP2007297313A (en) | Method for producing herbal medicine-granulated particle, and herbal medicine-granulated particle and tablet | |
| JP2006016329A (en) | Granular medicine | |
| JP4462476B2 (en) | Method for producing mixed granules | |
| JP4719899B2 (en) | Orally rapidly disintegrating tablets | |
| JP4945917B2 (en) | Core particles for drug-containing coatings | |
| JP2010265211A (en) | Coated caffeine particle and solid preparation for oral administration containing the same | |
| JP2015107951A (en) | Granules | |
| JP2019131614A (en) | Solid preparation | |
| JP6307874B2 (en) | Layering particles | |
| JP7419462B2 (en) | Oral solid composition | |
| JP6757596B2 (en) | Oral solid tablets | |
| JP2005343800A (en) | Coated caffeine particle, solid preparation and sleepiness-preventing medicine | |
| JP2008189634A (en) | Method for producing intraorally quickly disintegrable tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120712 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120928 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121023 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121105 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151130 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |